<DOC>
	<DOC>NCT00058994</DOC>
	<brief_summary>The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.</brief_summary>
	<brief_title>An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>anecortave acetate</keyword>
	<keyword>wet AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Maculopathy, Age-Related</keyword>
	<keyword>Age-Related Maculopathies</keyword>
	<keyword>Age-Related Maculopathy</keyword>
	<keyword>Maculopathies, Age-Related</keyword>
</DOC>